PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer
Citation
Zengin, M., Zergeroğlu, S., Okcu, O., & Benek, S. (2021). PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer. Cellular oncology (Dordrecht), 44(2), 423–432. https://doi.org/10.1007/s13402-020-00579-5Abstract
Background Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated.
Methods Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors.
Results We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS.
Conclusions Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted theapies.
